Cadonilimab+ Paclitaxel (Albumin-bound) Treat Advanced Gastric Adenocarcinoma With PD-(L)1 Inhibitors Resistance

计划入组 40 人 · 首次发布于 2023 年 11 月 7 日

SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC

计划入组 238 人 · 首次发布于 2025 年 4 月 8 日

Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer

计划入组 200 人 · 首次发布于 2025 年 3 月 5 日

PD-(L)-1(ILAb)

Oral PD-L1,DICE Therapeutics

PD-(L)-1 program (iLab)

PD-RX Pharmaceuticals, Inc.

United States

NHI-1

United States

CLEVELAND CLINIC ABUDHABI L L C

United Arab Emirates

Optimizing Outcomes for High-Risk, Non-Muscle-Invasive Bladder Cancer with PD-(L)1 Inhibitors

FDA Grants Fast Track Designation to OncoC4's PD-1/VEGF Bispecific Cesalatamig for PD-(L)1-Refractory NSCLC

Combination Immunotherapies Show Promise in Pancreatic Cancer Treatment